Navigation Links
Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
Date:3/17/2008

WASHINGTON and SAN DIEGO, March 17 /PRNewswire/ -- Even as investors maintain their strong interest in the life sciences sector, industry stakeholders are facing tough decisions, according to Pillsbury attorneys.

"Despite the current credit crunch in the U.S., life science organizations spanning biotechnology, pharmaceuticals and medical devices continue to enjoy relatively easy access to capital and growing markets compared to other areas of the economy," said San Diego partner John Wetherell, co-chair of Pillsbury's National Life Sciences Practice Team. "But concerns over where to hedge R&D bets, globalization's advantages and pitfalls, pivotal intellectual property concerns and shifting oversight and regulations in Washington raise some tough questions about where the industry is going."

Wetherell says one of the biggest questions revolves around upcoming patent procedure changes and reform laws likely to affect how inventors are recognized and the awarding of damages in infringement claims. While Congress and the Patent and Trademark Office (PTO) weigh patent revisions, the first series of patents on more than 70 common pharmaceuticals will expire, which begs the question about generics and how much patent holders stand to lose after investing so much money in research for these products. This is of particular concern given a changing regulatory environment in Washington, where authorities and legislators seek to revamp competing policy objectives and incentives intended to empower the industry and consumers, as well as protect patient safety.

"Given Presidential campaign polls showing that many voters favor some form of universal healthcare and the scope of such plans touted in Congress and on campaign trails, including debates over how best to negotiate lower costs for prescriptions drugs, pharmaceutical companies, universities and other life science leaders face significant risks and opportunities," said David C. Main, head of Pill
'/>"/>

SOURCE Pillsbury Winthrop Shaw Pittman LLP
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... Space ... the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity ... ... off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific ...
... , Full enrollment occurs five months ahead of schedule , ... /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced ... clinical study of its lead drug RVX-208. "The completion of ... months ahead of our original schedule, is a very exciting ...
... , , , , ... Feb. 8 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... China -based biotechnology company,focused on researching, developing, manufacturing and ... Panacor Bioscience Ltd. to develop and commercialize its,Nephoxil(R) pharmaceutical ...
Cached Biology Technology:Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 2Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 3Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 43SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
(Date:4/20/2014)... Neb., April 20, 2014 -- Using corn crop residue ... and can generate more greenhouse gases than gasoline, according ... Nature Climate Change . , The findings by a ... whether corn residue can be used to meet federal ... gas emissions. , Corn stover -- the stalks, leaves ...
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
(Date:4/18/2014)... For the past 20 years, researchers have published ... research findings have suggested that soil organic carbon can ... tillage systems to no-till systems. However, there is a ... in corn and soybean rotations without cover crops, small ... carbon stocks at the published rates. , "Some studies ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3MRI, on a molecular scale 2MRI, on a molecular scale 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4
... College of Medical Genetics (ACMG) will hold its 16th ... Sunday, March 29, 2009 at the Tampa Convention Center. ... healthcare is evolving at a dizzying pace and the ... opportunity for the medical and scientific media to learn ...
... then eating less may help you live longer. For ... of a new study predict the anti-aging strategy known ... dangerous exercise. "Today there are a lot of very ... this," said Raj Sohal, professor at the University of Southern ...
... A new strategy developed in the Neonatal and Infant ... premature infants and other newborns with severe swallowing difficulties ... study appearing in the February issue of the ... Nationwide Children,s were able to help 15 out of ...
Cached Biology News:Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29 2Eating less may not extend life 2Crib-side studies help struggling newborns go home without feeding tubes 2Crib-side studies help struggling newborns go home without feeding tubes 3
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Biology Products: